Marianna Cortese1,2,3, Trond Riise4,5, Kjetil Bjørnevik4,5, Alok Bhan6, Elisabeth Farbu6, Nina Grytten5,7, Ineke Hogenesch8, Rune Midgard9,10, Cecilia Smith Simonsen11, Wenche Telstad12, Alberto Ascherio13,14,15, Kjell-Morten Myhr5,7,16. 1. Department of Clinical Medicine, University of Bergen, Bergen, Norway. Marianna.Cortese@uib.no. 2. Department of Global Public Health and Primary Care, University of Bergen, Bergen, Norway. Marianna.Cortese@uib.no. 3. Norwegian MS Competence Center, Haukeland University Hospital, Bergen, Norway. Marianna.Cortese@uib.no. 4. Department of Global Public Health and Primary Care, University of Bergen, Bergen, Norway. 5. Norwegian MS Competence Center, Haukeland University Hospital, Bergen, Norway. 6. Department of Neurology, Stavanger University Hospital, Stavanger, Norway. 7. Kristian Gerhard Jebsen Center for MS Research, Department of Clinical Medicine, University of Bergen, Bergen, Norway. 8. Department of Neurology, Haugesund Hospital, Haugesund, Norway. 9. Department of Neurology, Molde Hospital, Molde, Norway. 10. Unit for Applied Clinical Research, Norwegian University of Science and Technology, Trondheim, Norway. 11. Department of Neurology, Drammen Hospital, Drammen, Norway. 12. Department of Neurology, Førde Hospital, Førde, Norway. 13. Department of Epidemiology, Harvard T. H. Chan School of Public Health, Boston, MA. 14. Department of Nutrition, Harvard T. H. Chan School of Public Health, Boston, MA. 15. Channing Division of Network Medicine of the Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA. 16. Norwegian MS Registry and Biobank, Haukeland University Hospital, Bergen, Norway.
Abstract
OBJECTIVE: To prospectively investigate potential signs of preclinical multiple sclerosis (MS) activity and when they are present prior to first symptom using data from a historical cohort. METHODS: We linked the cognitive performance of all Norwegian men born 1950-1995 who underwent conscription examination at age 18 to 19 years to the Norwegian MS registry to identify those later developing MS, and randomly selected controls frequency-matched on year of birth from the Norwegian Conscript Service database. In this nested case-control study, cognitive test scores were available for 924 male cases and 19,530 male controls. We estimated mean score differences among cases and controls (Student t test) and the risk of developing MS comparing lower to higher scores (Cox regression) in strata of years to clinical onset. RESULTS: Men developing first clinical MS symptoms up to 2 years after the examination scored significantly lower than controls (Δ = 0.80, p = 0.0095), corresponding to a 6 intelligence quotient (IQ)-point difference. Those scoring lowest, that is, >1 standard deviation below the controls' mean, had an increased MS risk during the 2 following years (relative risk = 2.81, 95% confidence interval = 1.52-5.20). Whereas results were similar for relapsing-remitting MS cases (RRMS), those developing primary-progressive MS (PPMS) scored a significant 4.6 to 6.9 IQ points lower than controls up to 20 years prior to first progressive symptoms. INTERPRETATION: RRMS may start years prior to clinical presentation, and disease processes in PPMS could start decades prior to first apparent progressive symptoms. Cognitive problems could be present in both MS forms before apparent symptoms. Apart from potential implications for clinical practice and research, these findings challenge our thinking about the disease. Ann Neurol 2016;80:616-624.
OBJECTIVE: To prospectively investigate potential signs of preclinical multiple sclerosis (MS) activity and when they are present prior to first symptom using data from a historical cohort. METHODS: We linked the cognitive performance of all Norwegian men born 1950-1995 who underwent conscription examination at age 18 to 19 years to the Norwegian MS registry to identify those later developing MS, and randomly selected controls frequency-matched on year of birth from the Norwegian Conscript Service database. In this nested case-control study, cognitive test scores were available for 924 male cases and 19,530 male controls. We estimated mean score differences among cases and controls (Student t test) and the risk of developing MS comparing lower to higher scores (Cox regression) in strata of years to clinical onset. RESULTS:Men developing first clinical MS symptoms up to 2 years after the examination scored significantly lower than controls (Δ = 0.80, p = 0.0095), corresponding to a 6 intelligence quotient (IQ)-point difference. Those scoring lowest, that is, >1 standard deviation below the controls' mean, had an increased MS risk during the 2 following years (relative risk = 2.81, 95% confidence interval = 1.52-5.20). Whereas results were similar for relapsing-remitting MS cases (RRMS), those developing primary-progressive MS (PPMS) scored a significant 4.6 to 6.9 IQ points lower than controls up to 20 years prior to first progressive symptoms. INTERPRETATION: RRMS may start years prior to clinical presentation, and disease processes in PPMS could start decades prior to first apparent progressive symptoms. Cognitive problems could be present in both MS forms before apparent symptoms. Apart from potential implications for clinical practice and research, these findings challenge our thinking about the disease. Ann Neurol 2016;80:616-624.
Authors: Kjetil Bjornevik; Kassandra L Munger; Marianna Cortese; Christian Barro; Brian C Healy; David W Niebuhr; Ann I Scher; Jens Kuhle; Alberto Ascherio Journal: JAMA Neurol Date: 2020-01-01 Impact factor: 18.302
Authors: Ruth Ann Marrie; Mark Allegretta; Lisa F Barcellos; Bruce Bebo; Peter A Calabresi; Jorge Correale; Benjamin Davis; Philip L De Jager; Christiane Gasperi; Carla Greenbaum; Anne Helme; Bernhard Hemmer; Pamela Kanellis; Walter Kostich; Douglas Landsman; Christine Lebrun-Frenay; Naila Makhani; Kassandra L Munger; Darin T Okuda; Daniel Ontaneda; Ronald B Postuma; Jacqueline A Quandt; Sharon Roman; Shiv Saidha; Maria Pia Sormani; Jon Strum; Pamela Valentine; Clare Walton; Kathleen M Zackowski; Yinshan Zhao; Helen Tremlett Journal: Nat Rev Neurol Date: 2022-07-15 Impact factor: 44.711
Authors: Tugba Kapanci; Kevin Rostásy; Martin Georg Häusler; Tobias Geis; Mareike Schimmel; Christiane Elpers; Jonas H Kreth; Charlotte Thiels; Stefan J Troche Journal: Mult Scler J Exp Transl Clin Date: 2019-12-11
Authors: Vladeta Ajdacic-Gross; Nina Steinemann; Gábor Horváth; Stephanie Rodgers; Marco Kaufmann; Yanhua Xu; Christian P Kamm; Jürg Kesselring; Zina-Mary Manjaly; Chiara Zecca; Pasquale Calabrese; Milo A Puhan; Viktor von Wyl Journal: Front Neurol Date: 2021-07-06 Impact factor: 4.003
Authors: Olga von Bismarck; Theresa Dankowski; Björn Ambrosius; Nicole Hessler; Gisela Antony; Andreas Ziegler; Muna-Miriam Hoshi; Lilian Aly; Felix Luessi; Sergiu Groppa; Luisa Klotz; Sven G Meuth; Björn Tackenberg; Muriel Stoppe; Florian Then Bergh; Hayrettin Tumani; Tania Kümpfel; Martin Stangel; Christoph Heesen; Brigitte Wildemann; Friedemann Paul; Antonios Bayas; Clemens Warnke; Frank Weber; Ralf A Linker; Ulf Ziemann; Uwe K Zettl; Frauke Zipp; Heinz Wiendl; Bernhard Hemmer; Ralf Gold; Anke Salmen Journal: Neurol Neuroimmunol Neuroinflamm Date: 2018-03-01
Authors: Rosalind Kalb; Meghan Beier; Ralph Hb Benedict; Leigh Charvet; Kathleen Costello; Anthony Feinstein; Jeffrey Gingold; Yael Goverover; June Halper; Colleen Harris; Lori Kostich; Lauren Krupp; Ellen Lathi; Nicholas LaRocca; Ben Thrower; John DeLuca Journal: Mult Scler Date: 2018-10-10 Impact factor: 6.312